ADAR1 Capital Management LLC Buys Shares of 106,000 Leap Therapeutics, Inc. (NASDAQ:LPTX)

ADAR1 Capital Management LLC purchased a new position in Leap Therapeutics, Inc. (NASDAQ:LPTX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 106,000 shares of the company’s stock, valued at approximately $305,000. ADAR1 Capital Management LLC owned about 0.28% of Leap Therapeutics at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of LPTX. Prosperity Wealth Management Inc. bought a new position in Leap Therapeutics in the fourth quarter worth approximately $63,000. HighTower Advisors LLC bought a new position in Leap Therapeutics in the 3rd quarter worth $65,000. HB Wealth Management LLC lifted its position in Leap Therapeutics by 103.2% during the fourth quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock valued at $150,000 after purchasing an additional 26,150 shares in the last quarter. LPL Financial LLC bought a new stake in Leap Therapeutics during the fourth quarter valued at about $218,000. Finally, Exome Asset Management LLC bought a new stake in Leap Therapeutics during the third quarter valued at about $264,000. Institutional investors own 30.46% of the company’s stock.

Leap Therapeutics Stock Up 10.0 %

NASDAQ LPTX opened at $0.29 on Tuesday. Leap Therapeutics, Inc. has a twelve month low of $0.22 and a twelve month high of $4.79. The business has a 50-day moving average price of $0.45 and a 200-day moving average price of $2.05. The firm has a market cap of $12.06 million, a price-to-earnings ratio of -0.15 and a beta of 0.22.

Leap Therapeutics (NASDAQ:LPTX) last posted its quarterly earnings results on Wednesday, March 26th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.02. Research analysts expect that Leap Therapeutics, Inc. will post -1.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on LPTX shares. Baird R W cut Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 29th. Robert W. Baird downgraded shares of Leap Therapeutics from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $9.00 to $1.25 in a report on Wednesday, January 29th. Finally, HC Wainwright reissued a “neutral” rating on shares of Leap Therapeutics in a research note on Thursday, March 27th.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.